{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:08:29Z","timestamp":1793999309954,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.ijantimicag.2009.09.013","type":"journal-article","created":{"date-parts":[[2009,11,9]],"date-time":"2009-11-09T09:06:03Z","timestamp":1257757563000},"page":"3-12","source":"Crossref","is-referenced-by-count":83,"title":["Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"35","author":[{"given":"Liang","family":"Beibei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mengli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xuhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2009.09.013_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s101560100019","article-title":"Surveillance of bacterial resistance among isolates in Shanghai in 1999","volume":"7","author":"Wang","year":"2001","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib4","doi-asserted-by":"crossref","unstructured":"National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470\u201385.","DOI":"10.1016\/j.ajic.2004.10.001"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2009.09.013_bib5","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1093\/jac\/dkn353","article-title":"Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001\u201306","volume":"62","author":"Hope","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1592\/phco.27.7.1001","article-title":"Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes","volume":"27","author":"Lodise","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib7","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/cc4946","article-title":"Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia","volume":"10","author":"Shorr","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jac\/dkp065","article-title":"Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom","volume":"63","author":"Gould","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib9","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","article-title":"Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin","volume":"350","author":"Hiramatsu","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0732-8893(99)00141-8","article-title":"Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin","volume":"36","author":"Wong","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib12","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.41.10.2132","article-title":"Mechanism of action of oxazolidinones: effect of linezolid and eperezolid on translation reactions","volume":"41","author":"Shinabarger","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0732-8893(01)00235-8","article-title":"Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby\u2013Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States","volume":"40","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0732-8893(02)00371-1","article-title":"Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998\u20132000","volume":"43","author":"Mutnick","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin\u2013dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1128\/AAC.45.6.1843-1846.2001","article-title":"Pharmacokinetics and tissue penetration of linezolid following multiple oral doses","volume":"45","author":"Gee","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or \u03b2-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1592\/phco.21.3.263.34198","article-title":"Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial","volume":"21","author":"Li","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib21","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1592\/phco.22.4.45S.33654","article-title":"Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections","volume":"22","author":"Li","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib22","first-page":"540","article-title":"Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis","volume":"18","author":"Willke","year":"2002","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/109629603764655290","article-title":"Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial","volume":"4","author":"Li","year":"2003","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijantimicag.2005.09.003","article-title":"Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA)","volume":"26","author":"Itani","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1G728","article-title":"Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections","volume":"40","author":"McKinnon","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/030079906X162700","article-title":"Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections","volume":"23","author":"Patanwala","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"9 Suppl.","key":"10.1016\/j.ijantimicag.2009.09.013_bib27","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/01.inf.0000086955.93702.c7","article-title":"Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates","volume":"22","author":"Deville","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"9 Suppl.","key":"10.1016\/j.ijantimicag.2009.09.013_bib28","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1097\/01.inf.0000086956.45566.55","article-title":"Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens","volume":"22","author":"Jantausch","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.amjsurg.2004.08.045","article-title":"Linezolid eradicates MRSA better than vancomycin from surgical-site infections","volume":"188","author":"Weigelt","year":"2004","journal-title":"Am J Surg"},{"issue":"9 Suppl.","key":"10.1016\/j.ijantimicag.2009.09.013_bib30","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/01.inf.0000088671.35064.7c","article-title":"Linezolid for the treatment of complicated skin and skin structure infections in children","volume":"22","author":"Yogev","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib31","first-page":"12","article-title":"Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study","volume":"47","author":"Grudinina","year":"2002","journal-title":"Antibiot Khimioter"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/500139","article-title":"Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer","volume":"42","author":"Jaksic","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","article-title":"Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"189","author":"Sharpe","year":"2005","journal-title":"Am J Surg"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib37","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib38","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijantimicag.2008.04.004","article-title":"Linezolid for the treatment of infections caused by Gram-positive pathogens in China","volume":"32","author":"Lin","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib41","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","article-title":"Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia","volume":"25","author":"Wunderink","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib42","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1378\/chest.08-0011","article-title":"Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus","volume":"134","author":"Wunderink","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib43","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1592\/phco.21.11.1010.34517","article-title":"Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid","volume":"21","author":"Kuter","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.09.013_bib45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909004361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909004361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T18:37:29Z","timestamp":1558636649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857909004361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0924857909004361"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.09.013","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}